Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Nymox Pharmaceutical Corporation (NYMX) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (NASDAQ: NYMX) of the January 26, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Nymox and the president and founder of the Company.
A complaint has been filed in the United States District Court for the District of New Jersey on behalf of all persons who purchased or acquired Nymox common stock between January 31, 2011 and November 2, 2014 (the “Class Period”).
The complaint alleges that the Company and its executives violated federal securities laws with respect to its statements concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period, Nymox misrepresented and/or failed to disclose that trials of its most promising investigational drug, NX-1207, had revealed factors that indicated the drug’s likely failure to achieve statistical significance.
On November 2, 2014, the Company announced that the two Phase 3 studies had to be halted because the drug failed to meet primary efficacy endpoints.
Following this news, the price of Nymox’s stock declined by $4.21 per share, or over 81%, to close on November 3, 2014 at $0.93 per share.
If you invested in Nymox common stock or options between January 31, 2011 and November 2, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Nymox’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.